https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-12-06 / Clin. Cancer Res. 2011 Mar;17(6):1603-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-12-06 / Clin. Cancer Res. 2011 Mar;17(6):1603-152010-12-06 00:00:002019-02-15 08:46:43Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-12-01 / Curr Opin Investig Drugs 2010 Dec;11(12):1399-408
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-12-01 / Curr Opin Investig Drugs 2010 Dec;11(12):1399-4082010-12-01 00:00:002019-02-15 08:49:21New approaches to the development of adenoviral dendritic cell vaccines in melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-12-01 / Anticancer Res. 2010 Dec;30(12):5091-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-12-01 / Anticancer Res. 2010 Dec;30(12):5091-72010-12-01 00:00:002019-02-15 08:46:02Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-11 / Cancer Immunol. Immunother. 2011 Feb;60(2):249-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-11 / Cancer Immunol. Immunother. 2011 Feb;60(2):249-602010-11-11 00:00:002019-02-15 08:49:22Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-11 / Cancer Immunol. Immunother. 2011 Jan;60(1):87-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-11 / Cancer Immunol. Immunother. 2011 Jan;60(1):87-972010-11-11 00:00:002019-02-15 08:50:09An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-04 / Clin. Dev. Immunol. 2010;2010:517493
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-04 / Clin. Dev. Immunol. 2010;2010:5174932010-11-04 00:00:002019-02-15 08:52:55Dendritic cell-based immunotherapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Expert Opin Biol Ther 2010 Nov;10(11):1539-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Expert Opin Biol Ther 2010 Nov;10(11):1539-532010-11-01 00:00:002019-02-15 08:40:15Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Neoplasia 2010 Nov;12(11):906-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Neoplasia 2010 Nov;12(11):906-142010-11-01 00:00:002019-02-15 08:52:56RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2240-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2240-22010-11-01 00:00:002019-02-15 08:52:01[WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-10-28 / Expert Opin Biol Ther 2010 Dec;10(12):1637-47
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-10-28 / Expert Opin Biol Ther 2010 Dec;10(12):1637-472010-10-28 00:00:002019-02-15 08:40:13Personalized cancer vaccines
